Compare · DFTX vs TLRY
DFTX vs TLRY
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Tilray Brands Inc. (TLRY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and TLRY operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $5.34B, about 10.0x TLRY ($532.5M).
- TLRY has been more active in the news (16 items in the past 4 weeks vs 12 for DFTX).
- TLRY has more recent analyst coverage (14 ratings vs 7 for DFTX).
- Company
- Definium Therapeutics Inc.
- Tilray Brands Inc.
- Price
- -
- -
- Market cap
- $5.34B
- $532.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 12
- 16
- Recent ratings
- 7
- 14
Tilray Brands Inc.
Tilray, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products. The company operates through five segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, Wellness Business, and Business Under Development. It provides medical and adult-use cannabis products; pharmaceutical and wellness products; beverage alcohol products; and hemp-based food and other wellness products. The company offers its products to retailers, wholesalers, patients, physicians, pharmacies, clinics, hospitals, governments, and researchers. It has operations in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company was formerly known as Aphria Inc. Tilray, Inc. was incorporated in 2018 and is based in New York, New York.
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
- BofA Securities initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics Announces New Employee Inducement Grants
- Amendment: SEC Form SCHEDULE 13G/A filed by Definium Therapeutics Inc.
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 36% to 237,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 20% to 603,282 units (SEC Form 4)
- Chief Financial Officer Roberts Brandi was granted 62,500 shares, increasing direct ownership by 30% to 271,987 units (SEC Form 4)
- Chief Executive Officer Barrow Robert was granted 375,000 shares, increasing direct ownership by 34% to 1,473,246 units (SEC Form 4)
- Chief Legal Officer Sullivan Mark was granted 62,500 shares, increasing direct ownership by 19% to 383,071 units (SEC Form 4)
Latest TLRY
- Award-Winning BrewDog Unleashes Liquid Visions, a Bold New Craft Beer Series Built to Light Up Retail Shelves
- President and CEO Simon Irwin D converted options into 1,212,168 shares and covered exercise/tax liability with 642,450 shares, increasing direct ownership by 77% to 1,309,031 units (SEC Form 4) to satisfy tax liability
- Chief Financial Officer Merton Carl A converted options into 168,452 shares and covered exercise/tax liability with 92,649 shares, increasing direct ownership by 54% to 215,556 units (SEC Form 4) (tax liability)
- Global General Counsel Gendel Mitchell converted options into 160,304 shares and covered exercise/tax liability with 84,962 shares, increasing direct ownership by 60% to 200,225 units (SEC Form 4) to cover taxes
- Chief Strategy Officer Faltischek Denise M converted options into 178,221 shares and covered exercise/tax liability with 94,459 shares, increasing direct ownership by 59% to 225,047 units (SEC Form 4) (tax withholding)
- BrewDog Wins Big at the 2026 World Beer Awards with a Sweeping Show of Brewing Excellence
- Tilray Strengthens Global Medical Cannabis Leadership with Major Production Increase to Meet International Demand
- BrewDog Unwraps Its 2026 Advent Calendar
- Tilray Medical Welcomes Progress in Germany’s Medical Cannabis Framework and Supports Continued Policy Development
- Montauk Brewing Company Expands Its Coastal Footprint with New North Shore Brewpub